Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 17 of 39, showing 5 Applications out of 192 total, starting on record 81, ending on 85

# Protocol No Study Title Investigator(s) & Site(s)

81.

ECCT/22/02/01   An Open label Inclacumab study
    An Open-Label Extension Study to Evaluate the Long-Term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial   
Principal Investigator(s)
1. Bernhards Ragama Ogutu
2. Fredrick Asirwa Chite
3. Videlis N nduba
4. Prof Jessie N Githanga
Site(s) in Kenya
1. Strathmore University Medical Centre (Nairobi City county)
2. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county)
3. KEMRI/CRDR (Nairobi City county)
4. KEMRI Siaya Clinical Research Annex (Siaya county)
5. Gertrude’s Children’s Hospital. (Nairobi City county)
6. Strathmore University Medical Centre (Nairobi City county)
 
View

82.

ECCT/22/03/09   GBT 132-Inclacumub PH3
    A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell Disease and Recurrent Vaso-occlusive Crises.   
Principal Investigator(s)
1. Videlis N Nduba
2. Bernhards Ragama Ogutu
3. Fredrick Asirwa Chite
Site(s) in Kenya
1. KEMRI Siaya Clinical Research Annex (Siaya county)
2. KEMRI/CRDR (Nairobi City county)
3. International Cancer Institute (ICI)-Eldoret (Uasin Gishu county)
4. Strathmore University Medical Centre (Nairobi City county)
 
View

83.

ECCT/22/01/04   SKYSCRAPER 07
    A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB WITH OR WITHOUT TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) IN PATIENTS WITH UNRESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA WHOSE CANCERS HAVE NOT PROGRESSED FOLLOWING DEFINITIVE CONCURRENT CHEMORADIOTHERAPY   
Principal Investigator(s)
1. Fredrick Chite Asirwa
2. Mansoor Saleh
Site(s) in Kenya
1. Aga Khan University, Nairobi (Nairobi City county)
2. International Cancer Institute (Uasin Gishu county)
 
View

84.

ECCT/21/12/07   GBT 132- Inclacumab Phase 3
    A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell Disease and Recurrent Vaso-occlusive Crises.   
Principal Investigator(s)
1. Bernhards Ragama Ogutu
2. Videlis N Nduba
3. Fredrick Asirwa Chite
Site(s) in Kenya
1. Strathmore University Medical Centre (Nairobi City county)
2. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county)
3. KEMRI/CRDR (Nairobi City county)
4. KEMRI Siaya Clinical Research Annex (Siaya county)
 
View

85.

ECCT/21/12/05   131 Inclacumab Ph 3 Trial.
    A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vasoocclusive Crises   
Principal Investigator(s)
1. Bernhards Ragama Ogutu
2. Fredrick Asirwa Chite
3. Videlis N Nduba
4. Prof. Jessie N Githanga
Site(s) in Kenya
1. Strathmore University Medical Centre (Nairobi City county)
2. KEMRI/CRDR (Nairobi City county)
3. KEMRI Siaya Clinical Research Annex (Siaya county)
4. Gertrude’s Children’s Hospital. (Nairobi City county)
5. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county)
 
View